{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:46:06Z","timestamp":1791931566505,"version":"4.3.4"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatologie"],"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Hintergrund<\/jats:title>\n                    <jats:p>Das Merkel-Zell-Karzinom (MCC) ist ein seltenes, hochaggressives neuroendokrines Hautkarzinom. Eine Therapie mit Avelumab (Programmed Death-Ligand 1 (PD-L1)-Antik\u00f6rper) ist im fortgeschrittenen Stadium etabliert. Daten aus dem Versorgungsalltag sind jedoch begrenzt.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ziel der Arbeit (Fragestellung)<\/jats:title>\n                    <jats:p>Es erfolgt Bewertung von Wirksamkeit und Sicherheit einer Therapie mit Avelumab bei fortgeschrittenem MCC in \u00d6sterreich.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Material und Methoden<\/jats:title>\n                    <jats:p>In dieser multizentrischen, retrospektiven Chart-Review-Studie wurden 49\u00a0Patient*Innen mit Merkel-Zell-Karzinom eingeschlossen, die zwischen 09\/2017 und 12\/2023\u202f\u2265\u20091\u00a0Zyklus Avelumab erhalten hatten. Prim\u00e4rer Endpunkt war das Real-World-progressionsfreie \u00dcberleben (rwPFS). Sekund\u00e4re Endpunkte umfassten das Real-World-Gesamt\u00fcberleben (rwOS), die Real-World-objektive Ansprechrate (rwORR), die Real-World-Ansprechdauer (rwDOR), die Zeit bis zum Ansprechen (rwTTR) sowie die Sicherheit; explorativ wurden die Zeit bis zum Therapieabbruch (rwTTD), univariate Subgruppenanalysen sowie post hoc multivariable Cox-Regressionen untersucht.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ergebnisse<\/jats:title>\n                    <jats:p>Das mediane rwPFS betrug 10,1\u00a0Monate (95\u202f%-KI 1,8\u201318,4), das mediane rwOS 22,9\u00a0Monate (95\u202f%-KI 5,0\u201340,8). Die rwORR lag bei 47,9\u202f% (95\u202f%-KI 34,5\u201361,7), die mediane rwDOR bei 19,2\u00a0Monaten. Unerw\u00fcnschte Ereignisse traten bei 71,4\u202f% der Patient*Innen auf und waren bei 48,6\u202f% der Betroffenen hochgradig. ir\/drAEs wurden bei 53,1\u202f% dokumentiert; 12,2\u202f% brachen die Therapie wegen unerw\u00fcnschter Ereignisse ab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diskussion<\/jats:title>\n                    <jats:p>Die Real-World-Ergebnisse best\u00e4tigen Wirksamkeit und ein erwartbares Sicherheitsprofil von Avelumab beim fortgeschrittenen MCC im klinischen Alltag. Unerw\u00fcnschte Ereignisse scheinen die Therapiedauer im Alltag zu limitieren und erfordern ein strukturiertes Monitoring und interdisziplin\u00e4res Management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00105-026-05788-x","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:38:43Z","timestamp":1791920323000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World-Ergebnisse der Behandlung mit Avelumab beim Merkel-Zell-Karzinom","Real-world outcomes of avelumab treatment for Merkel cell carcinoma"],"prefix":"10.1007","author":[{"given":"Magdalena","family":"Forstinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Barta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Brandlmaier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Hafner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Lammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Muigg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"\u00d6llinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Pinczker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Zahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timna","family":"Vith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Posch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,13]]},"reference":[{"key":"5788_CR1","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/ddg.14930_g","volume":"21","author":"JC Becker","year":"2023","unstructured":"Becker\u00a0JC, Beer\u00a0AJ, DeTemple\u00a0VK, Eigentler\u00a0T, Flaig\u00a0MJ, Gambichler\u00a0T, Grabbe\u00a0S, H\u00f6ller\u00a0U, Klumpp\u00a0B, Lang\u00a0S, Pf\u00f6hler\u00a0C, Posch\u00a0C, Prasad\u00a0V, Schlattmann\u00a0P, Schneider-Burrus\u00a0S, Ter-Nedden\u00a0J, Terheyden\u00a0P, Thoms\u00a0K, Vordermark\u00a0D, Ugurel\u00a0S (2023) S2k-Leitlinie \u2013 Merkelzellkarzinom \u2013 Update 2022. J\u00a0Dtsch Dermatol Ges 21:305\u2013317. https:\/\/doi.org\/10.1111\/ddg.14930_g","journal-title":"J Dtsch Dermatol Ges"},{"key":"5788_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.77","volume":"3","author":"JC Becker","year":"2017","unstructured":"Becker\u00a0JC, Stang\u00a0A, DeCaprio\u00a0JA, Cerroni\u00a0L, Lebb\u00e9\u00a0C, Veness\u00a0M, Nghiem\u00a0P (2017) Merkel cell carcinoma. Nat Rev Dis Primer 3:17077. https:\/\/doi.org\/10.1038\/nrdp.2017.77","journal-title":"Nat Rev Dis Primer"},{"key":"5788_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004904","volume":"10","author":"S Bhatia","year":"2022","unstructured":"Bhatia\u00a0S, Nghiem\u00a0P, Veeranki\u00a0SP, Vanegas\u00a0A, Lachance\u00a0K, Tachiki\u00a0L, Chiu\u00a0K, Boller\u00a0E, Bharmal\u00a0M (2022) Real-world clinical outcomes with avelumab in patients with Merkel cell carcinoma treated in the USA: a multicenter chart review study. J\u00a0Immunother Cancer 10:e004904. https:\/\/doi.org\/10.1136\/jitc-2022-004904","journal-title":"J Immunother Cancer"},{"key":"5788_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100290","volume":"6","author":"SP D\u2019Angelo","year":"2021","unstructured":"D\u2019Angelo\u00a0SP, Bhatia\u00a0S, Brohl\u00a0AS, Hamid\u00a0O, Mehnert\u00a0JM, Terheyden\u00a0P, Shih\u00a0KC, Brownell\u00a0I, Lebb\u00e9\u00a0C, Lewis\u00a0KD, Linette\u00a0GP, Milella\u00a0M, Xiong\u00a0H, Guezel\u00a0G, Nghiem\u00a0PT (2021) Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after \u3009\u202f5\u00a0years of follow-up. ESMO Open 6:100290. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100290","journal-title":"ESMO Open"},{"key":"5788_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103461","volume":"9","author":"SP D\u2019Angelo","year":"2024","unstructured":"D\u2019Angelo\u00a0SP, Lebb\u00e9\u00a0C, Mortier\u00a0L, Brohl\u00a0AS, Fazio\u00a0N, Grob\u00a0JJ, Prinzi\u00a0N, Hanna\u00a0GJ, Hassel\u00a0JC, Kiecker\u00a0F, von Heydebreck\u00a0A, G\u00fczel\u00a0G, Nghiem\u00a0P (2024) First-line avelumab treatment in patients with metastatic Merkel cell carcinoma: 4\u2011year follow-up from part\u00a0B of the JAVELIN Merkel 200 study. ESMO Open 9:103461. https:\/\/doi.org\/10.1016\/j.esmoop.2024.103461","journal-title":"ESMO Open"},{"key":"5788_CR6","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.0077","volume":"4","author":"SP D\u2019Angelo","year":"2018","unstructured":"D\u2019Angelo\u00a0SP, Russell\u00a0J, Lebb\u00e9\u00a0C, Chmielowski\u00a0B, Gambichler\u00a0T, Grob\u00a0JJ, Kiecker\u00a0F, Rabinowits\u00a0G, Terheyden\u00a0P, Zwiener\u00a0I, Bajars\u00a0M, Hennessy\u00a0M, Kaufman\u00a0HL (2018) Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage\u00a0IV Metastatic Merkel Cell Carcinoma. JAMA Oncol 4:e180077. https:\/\/doi.org\/10.1001\/jamaoncol.2018.0077","journal-title":"JAMA Oncol"},{"key":"5788_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-026-06485-x","volume":"152","author":"T Gambichler","year":"2026","unstructured":"Gambichler\u00a0T, Heinzer\u00a0E, Rached\u00a0NA, Schulze\u00a0HJ, Noah\u00a0K, Hofmann\u00a0SC, Wesselmann\u00a0U, Gutzmer\u00a0R, Boms\u00a0S, Susok\u00a0L, Weyer-Fahlbusch\u00a0SS, Kreuter\u00a0A, Hyun\u00a0J, M\u00fcller\u00a0VL, Auer\u00a0R, Becker\u00a0JC (2026) General health versus tumor stage: determinants of survival in Merkel cell carcinoma assessed by sentinel lymph node biopsy. J\u00a0Cancer Res Clin Oncol 152:100. https:\/\/doi.org\/10.1007\/s00432-026-06485-x","journal-title":"J Cancer Res Clin Oncol"},{"key":"5788_CR8","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ejca.2022.03.043","volume":"171","author":"ML Gauci","year":"2022","unstructured":"Gauci\u00a0ML, Aristei\u00a0C, Becker\u00a0JC, Blom\u00a0A, Bataille\u00a0V, Dreno\u00a0B, Del Marmol\u00a0V, Forsea\u00a0AM, Fargnoli\u00a0MC, Grob\u00a0JJ, Gomes\u00a0F, Hauschild\u00a0A, Hoeller\u00a0C, Harwood\u00a0C, Kelleners-Smeets\u00a0N, Kaufmann\u00a0R, Lallas\u00a0A, Malvehy\u00a0J, Moreno-Ramirez\u00a0D, Peris\u00a0K, Pellacani\u00a0G, Saiag\u00a0P, Stratigos\u00a0AJ, Vieira\u00a0R, Zalaudek\u00a0I, van Akkooi\u00a0ACJ, Lorigan\u00a0P, Garbe\u00a0C, Lebb\u00e9\u00a0C, European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), the European Organization for Research and Treatment of Cancer (EORTC) (2022) Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline - Update 2022. Eur J Cancer 171:203\u2013231. https:\/\/doi.org\/10.1016\/j.ejca.2022.03.043","journal-title":"Eur J Cancer"},{"key":"5788_CR9","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/S1470-2045(16)30364-3","volume":"17","author":"HL Kaufman","year":"2016","unstructured":"Kaufman\u00a0HL, Russell\u00a0J, Hamid\u00a0O, Bhatia\u00a0S, Terheyden\u00a0P, D\u2019Angelo\u00a0SP, Shih\u00a0KC, Lebb\u00e9\u00a0C, Linette\u00a0GP, Milella\u00a0M, Brownell\u00a0I, Lewis\u00a0KD, Lorch\u00a0JH, Chin\u00a0K, Mahnke\u00a0L, von Heydebreck\u00a0A, Cuillerot\u00a0JM, Nghiem\u00a0P (2016) Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol 17:1374\u20131385. https:\/\/doi.org\/10.1016\/S1470-2045(16)30364-3","journal-title":"Lancet Oncol"},{"key":"5788_CR10","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.2217\/fon-2017-0072","volume":"13","author":"P Nghiem","year":"2017","unstructured":"Nghiem\u00a0P, Kaufman\u00a0HL, Bharmal\u00a0M, Mahnke\u00a0L, Phatak\u00a0H, Becker\u00a0JC (2017) Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinoma. Future Oncol 13:1263\u20131279. https:\/\/doi.org\/10.2217\/fon-2017-0072","journal-title":"Future Oncol"},{"key":"5788_CR11","unstructured":"Statistik Austria, \u00d6sterreichisches Krebsregister (2025) Inzidenz des Merkelzellkarzinoms (ICD-O\u20113, Rev.\u00a02) in \u00d6sterreich. Unver\u00f6ffentlichte Auswertung, auf Anfrage \u00fcbermittelt am\u00a026.02.2025, Stand 10. Jan. 2025"},{"key":"5788_CR12","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1111\/jdv.12626","volume":"29","author":"I Vujic","year":"2015","unstructured":"Vujic\u00a0I, Marker\u00a0M, Posch\u00a0C, M\u00fchlehner\u00a0D, Monshi\u00a0B, Breier\u00a0F, Steiner\u00a0A, Ortiz-Urda\u00a0S, Rappersberger\u00a0K (2015) Merkel cell carcinoma: mitoses, expression of Ki-67 and bcl\u20112 correlate with disease progression. JEADV Clin Pract 29:542\u2013548. https:\/\/doi.org\/10.1111\/jdv.12626","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5788_CR13","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1111\/ddg.15214","volume":"21","author":"J Weilandt","year":"2023","unstructured":"Weilandt\u00a0J, Peitsch\u00a0WK (2023) Modern diagnostics and treatment of Merkel cell carcinoma. J\u00a0Dtsch Dermatol Ges 21:1524\u20131546. https:\/\/doi.org\/10.1111\/ddg.15214","journal-title":"JDDG J Dtsch Dermatol Ges"},{"key":"5788_CR14","doi-asserted-by":"publisher","first-page":"5228","DOI":"10.1158\/0008-5472.CAN-15-1877","volume":"75","author":"SQ Wong","year":"2015","unstructured":"Wong\u00a0SQ, Waldeck\u00a0K, Vergara\u00a0IA, Schr\u00f6der\u00a0J, Madore\u00a0J, Wilmott\u00a0JS, Colebatch\u00a0AJ, De Paoli-Iseppi\u00a0R, Li\u00a0J, Lupat\u00a0R, Semple\u00a0T, Arnau\u00a0GM, Fellowes\u00a0A, Leonard\u00a0JH, Hruby\u00a0G, Mann\u00a0GJ, Thompson\u00a0JF, Cullinane\u00a0C, Johnston\u00a0M, Shackleton\u00a0M, Sandhu\u00a0S, Bowtell\u00a0DDL, Johnstone\u00a0RW, Fox\u00a0SB, McArthur\u00a0GA, Papenfuss\u00a0AT, Scolyer\u00a0RA, Gill\u00a0AJ, Hicks\u00a0RJ, Tothill\u00a0RW (2015) UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas. Cancer Res 75:5228\u20135234. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-1877","journal-title":"Cancer Res"}],"container-title":["Die Dermatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-026-05788-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-026-05788-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-026-05788-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:02:34Z","timestamp":1791928954000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-026-05788-x"}},"subtitle":["Eine \u00f6sterreichische multizentrische Real-World-Studie","An Austrian multicenter real-world study"],"short-title":[],"issued":{"date-parts":[[2026,10,13]]},"references-count":14,"alternative-id":["5788"],"URL":"https:\/\/doi.org\/10.1007\/s00105-026-05788-x","relation":{},"ISSN":["2731-7005","2731-7013"],"issn-type":[{"value":"2731-7005","type":"print"},{"value":"2731-7013","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,13]]},"assertion":[{"value":"8 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.\u00a0Forstinger, M.\u00a0Barta, M.\u00a0Brandlmaier, C.\u00a0Hafner, M.\u00a0Lammer, L.\u00a0Muigg, A.\u00a0\u00d6llinger, A.\u00a0Pinczker, L.\u00a0Zahn, T.\u00a0Vith und C.\u00a0Posch geben an, dass kein Interessenkonflikt besteht.","order":1,"name":"Ethics","label":"Interessenkonflikt","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}}]}}